Kornimate/medical-research-clean huggingface dataset:
acute kidney injury in adult patients supported by va-ecmo

Conditions: Acute Kidney Injury; Cardiogenic Shock

Summary: post-cardiotomy cardiogenic shock (pccs) occurs in 2-6% of patients undergoing cardiac surgery, and 1% of cardiac surgery patients will require mechanical circulatory support using veno-arterial extracorporeal membrane oxygenation (va-ecmo). acute kidney injury is a frequent complication in this population and negatively impacts the survival. we aimed to determine whether the timing of ecmo implantation influence the renal prognosis of these patients.


Eligibility criteria:
inclusion criteria: * all patients admitted in post-operative of cardiac surgery * assisted by va-ecmo exclusion criteria: * chronic hemodialysis * death occurring within the first 48 hours of va-ecmo implantation * multiple va-ecmo during the same hospitalization.

Keywords: acute kidney injury ecmo post cardiogenic shock syndrome
glucose control in the icu using continuous glucose monitoring

Conditions: Critical Illness

Summary: stress hyperglycemia occurs in 50-85% of patients admitted to a medical intensive care unit (micu) and is associated with increased morbidity and mortality. however, randomized controlled trials examining the effects of strict glycemic control demonstrated conflicting results. a common finding in these trials was the high risk of hypoglycaemia. this randomized controlled trial evaluates the impact of real-time continuous glucose monitoring (rt-cgm) on glycemic control and risk of hypoglycemia in severely ill micu patients with an apache-ii (acute physiology and chronic health evaluation ii) score ≥20.


Eligibility criteria:
inclusion criteria: * patients admitted to a medical intensive care unit * age: ≥ 18 y , \< 75 y * apache ii (acute physiology and chronic health evaluation ii) score ≥ 20 * expected length of stay in icu \> 3 days exclusion criteria: * pregnancy * patient with a dnr (do not reanimate) code * surgical patient * no informed consent

Keywords: medical icu patients apache-ii score ≥20
phase iiatrials of ganmaokangning granules

Conditions: Epidemic Influenza

Summary: randomized, double-blind, double- simulation, positive drug-and-placebo-controlled, multicenter, phase iia clinical trials study about ganmaokangning granules in improving the symptoms of influenza.


Eligibility criteria:
inclusion criteria: * sign the informed consent; * male and female patients aged between 18 and 65 years old , there is no limit on the gender; * in line with the diagnostic criteria for pandemic influenza; * duration less than 48 (duration is defined as the time from onset to test drugs for the first time before, the onset time pointed out that now the axillary temperature 38.0 ℃, headache, muscle or joint pain, chills, fatigue, cough, sore throat and a stuffy nose eight any flu symptoms and signs in time); * the axillary temperature is 38.0 ℃ or higher; * nose and throat swabs rapid virus antigen test result is positive. exclusion criteria: * severe influenza and of patients with complications of influenza. * with the following any severe risk factors: a. with chronic respiratory diseases such as bronchial asthma, chronic obstructive pulmonary disease (copd), etc. b. with chronic diseases of the cardiovascular system, such as congestive heart failure, high blood pressure. c. with chronic metabolic and endocrine system diseases, such as poorly controlled diabetes (hba1c 7.0% or higher). d. with chronic kidney disease, chronic liver disease, blood system diseases, neurological and neuromuscular diseases (such as epilepsy, cognitive impairment, etc.). e. a weakened immune system, such as long-term use of immunosuppressive agents, hiv infection or tumor. f. under the age of 19, long-term aspirin use. g. the obese (bmi bmi \> 30). * with influenza complications, such as secondary bacterial pneumonia and other pathogenic bacteria and other viral pneumonia caused by pneumonia. * a history of peptic ulcer disease or gastrointestinal bleeding. * into the group received within 48 h before flu antiviral treatment. * into the group of 12 months before been vaccinated against the flu. * into the group used within 2 weeks before the monoamine oxidase inhibitors. * blood leukocyte count \> 10.0 x 109 / l, neutrophils ratio \> 80%, or the need for systemic antibiotic therapy. * for ganmaokangning granules, oseltamivir phosphate capsules, acetaminophen tablets, dextromethorphan hydrobromide capsule, ganmaokangning granules simulation agent or oseltamivir phosphate capsules simulation agent composition of allergy, or allergic constitution. * aminotransferase (ast/sgot) or alanine aminotransferase (alt/sgpt) ≥ 1.5 x upper limit normal (uln)， scr \> upper limit normal (uln). * doubt or does have a history of alcohol or drug abuse. * pregnancy (defined as the pregnancy test positive), nursing mothers, or past in family planning. * for nearly three months participated in other clinical trials of patients. * researchers think not appropriate to participate in this clinical subjects.
intravenous immunoglobulin in combination therapy with antibacterial agents for ssi of the lower digestive tract

Conditions: Peritonitis; Postoperative Complications

Summary: the purpose of this study is to assess the clinical usefulness of ivig in combination therapy with antibacterial agents for severe peritonitis after lower digestive tract surgery.


Eligibility criteria:
inclusion criteria: patients who have obvious symptoms and observation of post-surgical peritonitis, and meet the criteria described bellow. 1. patients with \>=38 degrees c, \>=15,000/mm3 or \ =10mg/dl of crp 2. patients who have no abscess on the abdominal image 3. patients who were administered antibacterial agents for 1 day or more, and show no sign of improvement 4. patients who are 20 years old or older 5. patients who have signed the agreement for participation in this study exclusion criteria: 1. patients who have a history of hypersensitivity to any of the ingredients of immunoglobulin products 2. patients who have a history of shock due to any of the ingredients of immunoglobulin products 3. patients who were administered immunoglobulin within 1 month before entry 4. patients who were administered antibacterial agents for 1 day or more, and show signs of improvement 5. patients with iga deficiency 6. patients with hereditary fructose intolerance 7. patients with history of allergy or adverse effect for antibacterial agents 8. patients who have underlying or concomitant disease that may seriously affect the assessment of this study 9. patients who are or could be pregnant 10. patients who have noninfectious fever, fungal infection or viral illness 11. other patients who are judged to be inadequate to participate in this study by their physician

Keywords: severe peritonitis ssi lower digestive tract surgery severe peritonitis after lower digestive tract surgery
study of pyx-201 in combination with pembrolizumab in advanced solid tumors

Conditions: Advanced Solid Tumours

Summary: the primary objective of this study is to determine the recommended phase 2 doses (rp2d(s)) and maximum tolerated dose (mtd) of pyx-201 in combination with pembrolizumab for participants with advanced solid tumors.


Eligibility criteria:
inclusion criteria 1. histologically or cytologically confirmed advanced solid tumors, including first-line (1l) head and neck squamous cell carcinoma (hnscc), advanced or metastatic triple negative breast cancer (tnbc), hormone receptor positive (hr+) and human epidermal growth factor receptor 2 negative breast cancer (her2- bc), gastric cancer (gc), cervical cancer, and second-line and higher (2l+) hnscc. 2. male or non-pregnant, non-lactating female participants age ≥18 years. 3. eastern cooperative oncology group performance status (ecog ps) of 0 to 1. 4. participant must have at least 1 measurable lesion per response evaluation criteria in solid tumours (recist) v1.1 criteria. 5. life expectancy of \>3 months, in the opinion of the investigator. 6. adequate hematologic function. 7. adequate hepatic function. 8. adequate renal function. 9. adequate coagulation profile. 10. clinical sites must conduct fresh tumor biopsy or provide participant's archived tumor tissue sample. exclusion criteria 1. known additional malignancy that is progressing or has required active treatment within the past 2 years. 2. known active central nervous system (cns) metastases and/or carcinomatous meningitis. 3. significant cardiovascular disease within 6 months prior to start of study drug. 4. evidence of an active systemic bacterial, fungal, or viral infection requiring treatment at the start of study drug. 5. known active hepatitis b virus (hbv), hepatitis c virus (hcv), human immunodeficiency virus (hiv) or acquired immunodeficiency syndrome (aids). 6. failure to recover to baseline severity or national cancer institute - common terminology criteria for adverse events (nci-ctcae) v5.0 grade ≤1 from acute non-hematologic toxicity due to previous therapy, prior to screening. 7. participants with active neuropathy of any grade per ctcae v5.0 at screening. 8. history of uncontrolled diabetes mellitus. 9. participants with immunodeficiency or active autoimmune disease that is contraindicated for pembrolizumab. 10. participants with a history of (noninfectious) pneumonitis/interstitial lung disease (ild) that required steroids or has current pneumonitis/ild. 11. prior solid organ or bone marrow progenitor cell transplantation. 12. prior high-dose chemotherapy requiring stem cell rescue. 13. previously received treatment with a programmed death-1 (pd-1)/l1 inhibitor any prior treatment with an agent directed to another stimulatory or co inhibitory t-cell receptor. 14. severe hypersensitivity (grade ≥3) to pembrolizumab and/or any of its excipients and/or pyx-201 and/or any of its excipients.

Keywords: advanced solid tumours pyx-201 pembrolizumab
preoperative topic diclofenac as a prevention of postoperative macular edema in patients with diabetic retinopathy

Conditions: Macular Edema; Cataract; Diabetic Retinopathy

Summary: diabetes has many negative effects on patients' general health. among many other consequences it speeds up the cataract formation and that is why diabetic patients need cataract surgery very often. the known side effect of cataract surgery even in otherwise healthy patients is postoperative edema of the back of the eye (what causes decrease of vision), which has greater incidence especially in patients who have diabetic eye problems. the cause of that might be the intraocular inflammation which was previously demonstrated to be significantly more prominent in patients with untreated diabetic eye problems. therefore we will examine if the 7 day use of anti-inflammatory eye drops prior to the cataract surgery prevent the formation of the edema of the back of the eye.


Eligibility criteria:
inclusion criteria: * presence of nonproliferative diabetic retinopathy * presence of the cataract (locs 2-3) exclusion criteria: * other chronic or acute eye diseases * hypersensitivity to any component of the diclofenac eye-drops patients on oral anticoagulant therapy * allergy to salycilates

Keywords: macular edema cataract diabetic retinopathy anti-inflammatory agents,non-steroidal
evaluate the role of anthracycline after radio therapy in patients with glioblastoma (pgbm).

Conditions: Glioblastoma

Summary: glioblastoma (gbm) and diffuse intrinsic bridge gliomas (dipg) only the most aggressive forms of cancer, and their prognosis remains bleak. currently, the standard of treatment is tmz concomitant with radiotherapy, and, at the end of combined treatment, as adjuvant therapy. in vitro and in vivo experimental studies have suggested that anthracyclines are effective antineoplastics for the treatment of gliomas. in patients with solid tumors treated with anthracyclines, continuous infusion administration compared with bolus administration has been shown to provide a better safety profile especially with regard to cardiotoxicity. based on this evidence, this study aims to evaluate the safety and antitumor activity of combined treatment with dox, wbrt (whole body radiotherapy), and tmz in pediatric and young adult patients affected by gmb


Eligibility criteria:
inclusion criteria: * patients with histological-molecular diagnosis according to who 2016 classification: idh-wildtype glioblastoma (9440/3), giant cell glioblastoma (9441/3), gliosarcoma (9442/3), epithelioid glioblastoma (9440/3), idh-mutated glioblastoma (9445/3), glioblastoma nos (9440/3), diffuse astrocytoma (9400/3), diffuse midline glioma h3 k27m mutated, including multifocal, metastatic or gliomatosis cerebri pictures of first diagnosis not previously treated (with chemo and radiotherapy) or treated only surgically (total, near partial, partial, biopsy). * males and females between the ages of 3 and 30 years old * life expectancy ≥ 12 months * karnofsky/lansky ≥ 80 % * adequate hematologic function: absolute leukocyte count ≥ 2.0 x 109/l, hemoglobin ≥ 10 g/dl, platelet count ≥ 50 x 109/l * adequate liver function: total bilirubin ≤ 2.5 x uln, alt/ast ≤ 5.0 x uln * adequate renal function:serum creatinine ≤ 1.5 x uln * written informed consent from the patient, parents or legal guardians * patient's willingness during treatment and ability to comply with the protocol exclusion criteria: * evidence of any other serious disease or condition that is a contraindication to study therapy (e.g. severe mental retardation, severe cerebral palsy, severe syndromes congenital syndromes, heart disease) * performance of a course of 1st-line chemotherapy at the same time as study initiation * concurrent participation in other research projects * pregnancy or lactation status * use of inappropriate contraceptive methods
context sensitivity in emotion regulation in post-traumatic stress disorder

Conditions: Complex Post-Traumatic Stress Disorder

Summary: this study will examine context sensitivity, composed of two sequential elements: (a) accurate classification of changing affective contextual demands, followed by (b) flexible selection of regulatory strategies that matches changing contextual demands, among complex ptsd vs. healthy controls.

the study will recruit adults with posttraumatic stress disorder (ptsd) due to a repetitive inter-personal trauma and healthy adult controls which do not meet dsm-5 criteria for ptsd and do not meet the clinical cutoff of anxiety and depression screening questionnaires. a compatibility check, filtering, verification of exclusion criteria and informed consent will occur via online self-report questionnaires. clinical questioners include: life event checklist (lec) - ptsd criteria a post-trauma checklist for dsm-5 (pcl) - ptsd symptoms patient health questionnaire (phq-9) - depression symptoms general anxiety disorder questioner (gad-7) - anxiety symptoms participants who pass the initial filtering, will be called and provided with an explanation about the study following which they received the online experiment. modified regulatory selection flexibility paradigm- included 3 blocks: (a) stimuli classification- 80 emotional words (equally distributed between high or low intensities) are presented and participants are asked classify each emotional word to high or low intensity. (b) regulatory selection- 40 emotional words (out of the 80 presented in block a) are presented and participants are instructed to behaviorally choose between distraction and reappraisal. (b) regulatory selection- 40 emotional words (the 40 remaining from block a) are presented, prior to regulatory selection, participants received accurate normed intensity classification of the word and then participants are instructed to behaviorally choose between distraction and reappraisal.

Eligibility criteria:
inclusion criteria: * native hebrew speakers * age between 18 - 65 * normal or corrected to normal vision * computer and internet access * group 1: diagnosis of ptsd according to the dsm-5 * group 2: gad and phq scores (score\<10), no diagnosis of ptsd according to the dsm-5 exclusion criteria: * psychosis * substance dependence or abuse other than nicotine * neurological condition

Keywords: emotion regulation
phase iii study treatment of cll b and c

Conditions: Leukemia, Lymphocytic, Chronic

Summary: goelams llc98 is a prospective randomized trial comparing in previously untreated b and c binet stages b-cll and on an intent to treat basis two strategies. conventional chemotherapy consisted of six monthly courses of chop, followed by 6 chop courses every other 3 months in case of response. experimental arm consisted of high dose therapy with autologous cd34+ purified progenitor cell support, used as consolidation of complete remission or very good partial response obtained after 3 monthly courses of chop, followed by 3 to 6 monthly-courses of fludarabine in case of insufficient response.

the aim of the prospective randomized goelams llc 98 trial reported here was to compare two therapeutic strategies in previously untreated b and c binet stages b-cll patients less than 60 years old. conventional chemotherapy (arm a) consisted of six monthly courses of chop, i.e. vincristin iv 1 mg/m2 on day 1, doxorubicin iv 25 mg/m2 on day 1, cyclophosphamide (cy) 300 mg/m2 and prednisone 40 mg/m2 both given orally from day 1 to day 5, followed by 6 chop courses every other 3 months in case of response. fludarabine (25 mg/m2 /d iv for 5 consecutive days) was used in case of non response (stable disease or progression) after 3 chop courses. this conventional therapy was compared to high dose therapy with autologous cd34+ purified progenitor cell support (arm b), used as consolidation of complete remission (cr) or very good partial response (vgpr, defined by \>50 % tumoral response and bone marrow lymphocyte infiltration \<30%) obtained after 3 monthly courses of chop. in the absence of cr or vgpr, 3 to 6 monthly-courses of fludarabine were performed before mobilization with cy 4 g/m2 + g-csf administration. the conditioning regimen included tbi 12 gy and cy 60 mg /kg /d for 2 days.

Eligibility criteria:
inclusion criteria: * cll with lymphocitis \> 15.10 9/l * b-cll stage b or c * patients \> 18 years old and \< 60 years old * no previous treatment of cll * ecog performance status \< 2 * good cardiac function * patient's written informed consent exclusion criteria: * b-cll stage a * age \> 60 years old * previous treatment of cll * ecog performance status \> 2 * cardiac or pneumo insufficency * hepatic or renal insufficency * seropositivity hiv * previous other malignancy * fertile male and female patients who cannot or do not wish to use an effective method of contraception * any coexisting medical or psychological condition that would preclude participation to the required study procedures * not signed patient's informed consent

Keywords: cll
psychotherapy for intermittent explosive disorder

Conditions: Anger; Intermittent Explosive Disorder

Summary: the goal of this study is to examine the effectiveness two forms of psychotherapy (also known as "talk therapy" ) for individuals with anger and aggression problems. anger and aggression are everywhere - on the road, in the schools, at little league games, at home, and at work. in this study we are testing usefulness of anger management techniques in reducing symptoms of intermittent explosive disorder (ied) and impulsive, aggressive behavior.

qualified participants will be randomly assigned to 12 1-hour sessions of either cognitive-behavioral therapy or supportive psychotherapy. participation in this study will require 13 visits over approximately 4 months with a 3 follow-up session. therapy is provided at no cost and each study participant will receive a comprehensive psychological assessment. two types of talk therapy are being offered in this study. one form of therapy focuses on thought and behaviors associated with anger and aggression. this type of therapy is known as cognitive behavioral therapy. the other type of therapy focuses on the individuals' feeling about their anger /aggression and the situations that lead to this anger. this is known as supportive therapy. the form of therapy you are given will be randomly determined (like by flipping of a coin).

Eligibility criteria:
inclusion criteria: * have problems with anger, temper outbursts, being irritable, getting in trouble at work or at home because of impulsive/aggressive behavior. * between the ages of 18 and 55. * meet other eligibility requirements as outlined by the research protocol. exclusion criteria: * lifetime diagnosis of psychosis or bipolar disorder * current diagnosis of substance dependence or major depressive disorder. * current suicidal or homicidal ideation, * recent use of selective serotonin reuptake inhibitors (past month) or other psychotropic medication (past two months) * recent psychotherapy for aggression (past six months.)

Keywords: anger intermittent explosive
rituximab after autologous stem cell transplant for relapsed b-cell non-hodgkin's lymphoma

Conditions: Non-Hodgkin's Lymphoma; Diffuse Large Cell Lymphoma; Mantle Cell Lymphoma; Transformed Lymphoma; Other Subtypes of B-cell Lymphoma; Lymphoma

Summary: conventional therapy is effective for diffuse aggressive lymphomas and low grade lymphomas, but is limited by relapse occurs in 40 to 50% of subjects. this study assesses autologous stem cell transplant (asct) supplemented with high-dose therapy increases the event-free survival in diffuse aggressive lymphomas and low grade lymphomas, as an alternative to the limitations of conventional therapy. preliminary studies with rituximab in low grade lymphomas indicate a response rate of about 50% with very little toxicity. rituximab is hypothesized to be a candidate for post-transplant therapy because the majority of malignant lymphomas express the cd20 antigen; rituximab has impressive independent anti-tumor activity; and the antibody has little toxicity outside of the acute administration.

the first 4 subjects received rituximab weekly for 4 weeks at the standard dose of 375 mg/m2, starting 6 weeks after asct transplant. after an observation period to assess acute and late toxicity for the first 4 subjects, subsequent subjects received induction as above followed by an additional 4 week course at 6-months post-asct.

Eligibility criteria:
inclusion criteria: * b-cell, cd20+ nhl * evidence of engraftment post-autologous peripheral blood stem cell transplant (pbsc-t), aka autologous stem cell transplant (asct) * eastern cooperative oncology group (ecog) performance status 0 to 1 * creatinine \< 2 mg/dl * bilirubin \< 2.0 mg/dl * liver function tests (lfts) \< 5 x upper limit of normal (uln) exclusion criteria: * graft source from bone marrow * non-responders \[progressive disease (pd) or stable disease (sd)\] to prior anti-cd20 therapy * pd after asct * post-asct radiotherapy * concomitant treatment with radiotherapy, chemotherapy or immunotherapy including rituximab * evidence of active pneumonitis * evidence of active infection * concurrent prednisone or other systemic steroid medication * nitrosourea therapy within 6 weeks of the first treatment with rituximab * presence of anti-murine antibody (hama) reactivity

Keywords: non-hodgkin's lymphoma diffuse large cell lymphoma mantle cell lymphoma transformed lymphoma other subtypes of b cell lymphoma recurrent lymphoma